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Introduction
LKB1 (STK11) was initially identified as the tumor suppressor gene 
mutated in Peutz-Jeghers syndrome (PJS), a hereditary, autoso-
mal dominant condition characterized by a dramatically elevated 
(15–20×) incidence of cancer (1, 2). Interestingly, individuals with 
PJS (who harbor monoallelic germline LKB1 mutations) have 
a propensity to develop epithelial malignancies (i.e., carcino-
mas) — particularly of the lung and uterus — but not sarcomas or 
lymphomas (3–5). Subsequent studies found that somatic LKB1-
inactivating mutations are common in carcinomas of diverse ana-
tomic sites (6–8). In human tumors (8, 9) and diverse conditional 
mouse models (3, 6, 8, 10–12), LKB1 loss is associated with rapid 
disease progression and spread, leading to unfavorable clinical 
outcomes across tumor types. LKB1 protein stability and activ-
ity are regulated by diverse posttranslational mechanisms (13, 
14), and decreased LKB1 protein expression in primary tumors 
in various anatomic locations correlates with poor prognosis (10, 
15–18), suggesting that diverse mechanisms in addition to direct 
mutational inactivation can lead to loss of LKB1 activity in cancer. 
The LKB1 locus (19p13.3) undergoes frequent loss of heterozygos-
ity in cancers; for example, 19p13.3 is the most frequently deleted 
chromosomal region in endometrial cancer (19) and is also recur-
rently deleted in lung cancer (20). Monoallelic LKB1 inactivation 
can lead to loss-of-function phenotypes, and LKB1 can function as 
a haploinsufficient tumor suppressor locus (21).
LKB1 is a highly conserved serine/threonine master upstream 
kinase activating the AMPK-related family of kinases (AMPK-
RKs), comprising the AMPK, BRSK, MARK, NUAK, and SIK sub-
families (5, 22). LKB1 phosphorylates the AMPK-RKs at conserved 
consensus sequences. The principal LKB1 phosphorylation site in 
AMPKα is threonine 172 (Thr172), a residue that lies in the acti-
vation loop of the AMPKα catalytic domain. Thr172 and its analo-
gous residues in the other AMPK-RKs can also be phosphorylated 
by other kinases, such as CaMKKβ (23). LKB1 function is closely 
tied to AMPK, a regulator of cellular metabolism under condi-
tions of energy deprivation, and some of LKB1’s actions as a tumor 
suppressor are mediated by its control of cellular metabolism 
and growth via AMPK and mTOR. However, LKB1 also controls 
diverse biological pathways relevant to cancer via other members 
of the AMPK-RK family. For example, LKB1 regulates epithelial 
cell polarity via the MARK kinases and axon branching via the 
NUAK kinases (24). LKB1 also controls cell migration along extra-
cellular matrix cues (haptotaxis) — via the MARK kinases (25). 
Thus, LKB1 functions as a tumor suppressor through a combina-
tion of AMPK-dependent and -independent pathways. Loss of 
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monogenic constitution, make it particularly attractive for inves-
tigations into the diverse biological manifestations of LKB1’s 
functions as a tumor suppressor.
Unexpectedly, our human cell line studies combined with 
detailed analyses of this model implicated LKB1 in the control of 
the tumor microenvironment (TME). We found that LKB1 loss led 
to abnormal patterns of gene expression in endometrial epitheli-
um characterized by misregulation of secreted factors, suggesting 
a novel LKB1 function in regulating the TME. Specifically, loss of 
LKB1 in endometrial epithelium led to the abnormal production 
of the proinflammatory cytokine chemokine (C-C motif) ligand 
2 (CCL2). CCL2 exerted systemic effects, leading to the recruit-
ment of protumorigenic macrophages. Finally, investigations 
conducted on a large number of human endometrial specimens 
lent further support to a model where LKB1 regulates the TME via 
CCL2-dependent recruitment of macrophages.
Results
Systematic identification of aberrantly expressed transcripts in endo-
metrial epithelial cells following LKB1 loss. In addition to its previ-
ously mentioned functions, LKB1 has potent effects in shaping the 
cellular transcriptome through multiple mechanisms, including 
direct phosphorylation of cAMP response element-binding pro-
tein–regulated (CREB-regulated) transcription activators (28, 29), 
phosphorylation by AMPK of diverse transcriptional activators 
such as the forkhead box, subgroup Os (FOXOs) (30), and sup-
pression of Snail1 (31), MYC (32), and Wnt signaling (33). We thus 
sought to identify transcripts whose aberrant expression follow-
either LKB1 or AMPK function elicits a number of cancer-associ-
ated metabolic phenotypes, including enhanced aerobic glycolysis 
and macromolecular biosynthesis (26).
We previously developed a mouse model of uterine cancer 
based on conditional inactivation of LKB1 in the endometrial epi-
thelium. One of the remarkable properties of this model is that 
inactivation of a single tumor suppressor — LKB1 — is sufficient 
to give rise to endometrial adenocarcinomas with complete pen-
etrance and short latency. These LKB1-deficient uterine tumors 
progress swiftly, leading to death in all animals (11). In contrast, 
most cancers require multiple cooperating mutations, and in 
virtually all mouse cancer models described to date, concurrent 
genetic “hits” are needed to give rise to invasive cancers (12). For 
example, homozygous inactivation of LKB1 alone does not lead to 
lung cancer or even precancers, whereas LKB1 inactivation com-
bined with KRAS activation or PTEN inactivation provokes lung 
cancers with 100% incidence (6, 27). In our LKB1-based endo-
metrial cancer model, pharmacologic inhibition of mTOR slowed 
tumor progression, implicating AMPK as an important effector of 
LKB1 in endometrial cancer (11). However, the aggressive nature 
of these LKB1-driven uterine tumors is not readily explained by 
misregulation of the AMPK/mTOR axis alone, particularly as the 
tumors were unusually well differentiated and no overt defects in 
cellular polarity were observed (11). These paradoxical findings 
and the particularly aggressive tumor progression phenotype sug-
gested the existence of novel biological activities and unknown 
tumor-suppressing functions under the control of LKB1. Fur-
thermore, several attributes of this mouse model, including its 
Figure 1. Discovery and validation of transcripts regulated by LKB1 in endometrial epithelium by gene-expression profiling. (A) Western blot of immor-
talized, nontransformed EM cells stably transduced with lentivirus encoding either nontarget shRNA or 1 of 2 different LKB1 shRNAs (shRNA1, shRNA2) 
that resulted in efficient LKB1 knockdown. LKB1 knockdown led to lower pAMPK levels, as expected, and modest effects on the levels of the phosphory-
lated forms of downstream mTOR-signaling components pS6 or p4EBP1. (B) Venn diagram of stably transduced cell lines showing the number of genes 
differentially expressed following LKB1 knockdown with the 2 shRNAs at a threshold of 3× or greater. P < 0.05 (Illumina Microarray Human HT-12 v4 
BeadChip, n = 3 biological replicates per shRNA). There was significant overlap (n = 35; P < 0.0001 per hypergeometric test) among differentially expressed 
genes following shRNA1 and shRNA2 knockdown (n = 53 and 121, respectively, among n = 18,281 genes represented in microarray), demonstrating that 
our experimental strategy was capable of identifying bona fide LKB1 targets. (C) Validation of gene-expression alterations by qRT-PCR, ΔΔCt method, 
depicting the mean fold change of shRNA1 and shRNA2 per gene analyzed (n = 3 independent samples distinct from those used for microarray expression 
profiling). Note that all gene-expression changes were consistent with the microarray data and also that LKB1, which is downregulated as expected, serves 
as an internal control. CCL2 showed the greatest alteration in expression levels per both microarray and RT-PCR among the subset of genes selected for 
validation. Error bars represent SEM.
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exhibiting changes in abundance of more than 3× were tabulated. 
With these criteria, shRNA2 consistently yielded more than twice 
as many targets as shRNA1 (121 vs. 53), which may reflect addi-
tional “off-target” effects with shRNA2. However, more than 
half of the genes identified with shRNA1 (36/53, or 68%) were 
also identified with shRNA2, clearly demonstrating that most of 
the tabulated genes were deregulated as a consequence of LKB1 
knockdown (Supplemental Table 1). These observations thus vali-
dated the overall gene discovery strategy of using 2 nonoverlap-
ping shRNAs to filter out off-targets (Figure 1B, P < 0.0001). Nota-
bly, changes in transcript abundance for all 36 genes occurred with 
the same directionality (i.e., either up or down) with both shRNAs, 
further validating our data sets. Finally, LKB1 itself was among 
the common shRNA1/2 tabulated gene sets, serving as an internal 
control (Supplemental Table 1).
To determine whether LKB1 regulation of the transcriptome 
might relate to distinct biological processes, gene ontology analy-
sis was performed on these tabulated genes. Gene ontology terms 
for which significant enrichment was observed in the identified 
gene set included “receptor binding” (P = 7 × 10–4) and “structural 
composition of the extracellular region of cells” (i.e., secreted fac-
tors) (P = 7 × 10–6) (Supplemental Table 2). The regulation of some 
extracellular factors such as MMP12 by LKB1 in endometrial cells 
ing LKB1 loss contributed to LKB1-dependent endometrial carci-
nogenesis. We stably transduced immortalized, nontransformed 
endometrial epithelial (EM) cells (34) with lentiviruses encoding 
either nontargeted shRNA or 1 of 2 nonoverlapping LKB1 shRNAs. 
Western blotting confirmed efficient LKB1 knockdown in each 
LKB1 shRNA cell line (shRNA1 and shRNA2) compared with the 
nontarget shRNA cell line (Figure 1A). As expected, LKB1 knock-
down resulted in hypophosphorylation of its canonical target 
AMPK (at Thr172), with more modest effects on the phosphory-
lation status of downstream components of the AMPK/mTOR 
pathway (S6 and 4EBP1). Interestingly, LKB1 knockdown did not 
by itself result in obvious phenotypic changes in EM cells such as 
alterations in growth rate or motility (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI82152DS1), consistent with the idea that additional genetic 
changes are needed to transform EM cells and in agreement with 
studies showing that LKB1 has a relatively modest impact on cell 
proliferation and instead acts as a tumor suppressor principally 
through its control of other biological processes (6, 35).
Total RNA was prepared from the 3 cell lines and subjected to 
transcriptional profiling with Illumina BeadChip Human HT-12 v4 
arrays (n = 3 biological replicates per cell line, a total of 9 arrays). 
Signals were normalized to the nontarget controls, and transcripts 
Figure 2. LKB1 suppresses CCL2 production by human EM cells via an AMPK-dependent mechanism. (A) Human CCL2 ELISA of conditioned media har-
vested 24 hours after plating of EM cells previously transduced with lentivirus. LKB1 knockdown led to a significant increase of CCL2 in the media (n = 3 
biological replicates per experiment). (B) Human CCL2 ELISA on conditioned media containing AICAR (0.5 mM), metformin (5 mM), or vehicle (PBS) only. 
AICAR or metformin significantly reduced CCL2 secretion 24 hours after addition of drug (n = 3 biological replicates). (C) Representative Western blot of 
lysates from cells shown in panel B revealing partial restoration of pAMPK levels. (D) Human CCL2 ELISA on conditioned media harvested 24 hours after 
plating cells transduced with control or AMPKα1/2-shRNA lentivirus. AMPK knockdown led to a significant increase in CCL2 (n = 3 biological replicates 
per experiment). (E) Representative Western blot of lysates from cells shown in D showing knockdown of AMPK and undetectable pAMPK levels.  
*P < 0.05; **P < 0.001; ***P < 0.0001, Student’s t test. Error bars = SEM.
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the Illumina analysis, as well as 6 other genes selected at random. 
These analyses were conducted on cells and RNA samples pre-
pared independently from those used for the initial profiling. All 8 
genes showed changes in magnitude (i.e., up or down) consistent 
with those observed in the Illumina BeadChip analyses (Figure 
1C). These analyses also confirmed the downregulation of LKB1 
transcripts and the upregulation of CCL2 transcripts following 
LKB1 knockdown (Figure 1C).
CCL2 was a particularly intriguing candidate as a mediator 
of LKB1-driven endometrial tumor progression. First, the chang-
es in CCL2 transcript levels were dramatic, more than a 10-fold 
increase (Supplemental Table 1 and Figure 1C). Second, CCL2 
(also known as monocyte chemoattractant protein-1 [MCP-1]) is 
a major inflammatory chemokine with important if incompletely 
understood roles in tumor progression, particularly in breast and 
prostate cancer, where it is largely protumorigenic (38, 39). Among 
other functions, CCL2 is a major macrophage chemoattractant 
and recruits macrophages in diverse forms of tissue damage (40). 
was not completely unanticipated, as prior studies have implicated 
LKB1 in the transcriptional regulation of secreted proteins, includ-
ing tissue metalloproteases (36). Nonetheless, a significant role 
of LKB1 in regulating secreted chemokines such as CCL2 has not 
been previously documented. We also note that several genes in 
the common set encode factors that modulate Wnt or Hedgehog 
signaling (e.g., WNT2, SMOOTHENED, SFRP1), consistent with 
prior studies implicating LKB1 in the regulation of these pathways 
(33, 37); however, related gene ontology terms did not achieve 
statistical significance. Our results suggest a broader biological 
function for LKB1 in regulating the extracellular environment by 
secreted factors than previously anticipated.
Validation of targets deregulated following LKB1 loss and identifi-
cation of the chemokine CCL2 as a biologically relevant candidate. To 
confirm alteration of transcript levels, we employed quantitative 
reverse-transcriptase PCR (qRT-PCR). Eight genes were selected 
for this analysis, including LKB1 and CCL2, which showed the 
greatest fold alteration in expression levels among all genes in 
Figure 3. Conditional Lkb1 knockout in murine endometrial epithelium results in endometrial cancers characterized by high CCL2 production. All experi-
ments were conducted in conditional knockout Lkb1–/– and sibling control Lkb1+/+ female mice at 12 weeks of age, the time point at which myometrial inva-
sion first occurs in this well-characterized model. Tissues were harvested at proestrus. (A) ELISA of serum or uterine protein lysates showing a significant 
increase of CCL2 levels following Lkb1 deletion (n = 14 Lkb1+/+, n = 24 Lkb1–/–). (B) CCL2 levels in tumor lysates (per ELISA) plotted against tumor mass from 
Lkb1–/– animals, showing a direct correlation between tumor mass and CCL2 levels (n = 24 mice, Pearson coefficient r2 = 0.39 with P = 0.001 per 2-tailed  
t test). (C) CCL2 expression in endometrial epithelium by image analysis (regions analyzed correspond to those enclosed by dashed lines in the next panel). 
Tissue sections were stained with a validated CCL2 antibody, and green CCL2 signal quantitation was performed using ImageJ (http://imagej.nih.gov/ij/) 
(n = 6 animals per experiment). Expression was normalized to the background signal present in Ccl2–/–; Lkb1+/+ uterine epithelium. (D) CCL2 immunofluo-
rescence of uterine tissue sections. s, stroma; e, epithelium. Asterisks denote basal CCL2 expression. Two different regions are shown for each genotype. 
(E) LKB1 and pAMPK (Thr172) immunohistochemistry of uterine tissue sections from Lkb1+/+ and Lkb1–/– mice. As expected, Lkb1 deletion in endometrial 
epithelium resulted in undetectable LKB1 protein as well as reduced pAMPK compared with control siblings. Statistical significance in A and C was deter-
mined by Student’s t test. *P < 0.005; **P < 0.001. Scale bars: 50 μm. Error bars = SEM.
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Lkb1f/f females (abbreviated hereafter as Lkb1–/–) developed inva-
sive endometrial adenocarcinomas beginning at 12 weeks of age, 
whereas sibling control Lkb1f/f females not harboring Sprr2f-Cre 
(abbreviated hereafter as Lkb1+/+) never developed cancers. To 
study early tumor progression, mice were euthanized at 12 weeks 
of age, the time point coinciding with the earliest appearance of 
invasive cancer, but prior to the formation of advanced, bulky 
tumors. Per ELISA, Lkb1–/– uterine lysates contained significantly 
more CCL2 than Lkb1+/+ sibling controls (Figure 3A). Interestingly, 
CCL2 levels were also increased in the peripheral blood (serum) 
of Lkb1–/– females, consistent with the idea that CCL2 produced by 
the tumorous uteri enters the circulation and thus could (a) exert 
systemic effects and (b) serve as a useful cancer biomarker of 
disease progression (Figure 3A). CCL2 concentrations showed a 
significant correlation with uterine tumor mass at 12 weeks of age 
(P = 0.001, r2 = 0.39) (Figure 3B).
To further define the cellular source of CCL2 within uteri, tis-
sue sections were immunostained with a validated CCL2 antibody 
(45). In control animals, CCL2 signals were weak, being limited 
to sporadic (and likely nonspecific) signals in the endometrial 
stromal cells and occasional faint signals in the apical cytoplasm 
(Figure 3D). In contrast, there was increased CCL2 immunore-
activity in Lkb1–/– uterine epithelium, predominantly in the apical 
cytoplasm, consistent with a secreted protein, although occasional 
cells exhibited some basal CCL2 localization (Figure 3D). In Ccl2-
deficient animals (described below), the CCL2-associated signals 
were abolished, confirming the specificity of immunodetection in 
the epithelium. Image analyses (n = 6 animals per genotype) con-
firmed these observations (Figure 3C). Finally, we documented 
AMPK hypophosphorylation in the LKB1-deficient epithelium 
(Figure 3E), confirming that AMPK is a bona fide physiologic tar-
get of LKB1 in vivo, as previously reported (46, 47), and indicating 
that the observed changes in CCL2 are likely AMPK dependent, as 
was the case in vitro (Figure 2, B and C).
Increased macrophage recruitment in Lkb1-driven endometrial 
cancers and their protumorigenic role. This increased production of 
CCL2 and its known function as a proinflammatory chemokine 
This finding suggests that LKB1 may have an unexpected role in 
modulating the TME through the control of intratumoral CCL2 
levels. Furthermore, the significant upregulation of a potentially 
protumorigenic secreted factor such as CCL2 appeared plausible 
as a mechanism underlying the incompletely understood tumor-
promoting actions of LKB1 inactivation.
As a first step in further exploring this possibility, CCL2 
ELISAs were performed on tissue culture media conditioned for 
24 hours. LKB1 knockdown with shRNA1 and -2 resulted in 14× 
and 7.0× increased concentrations of CCL2 in the media relative 
to the control nontarget shRNA (Figure 2A). Furthermore, addi-
tion to the media of 5-aminoimidazole-4-carboxamide ribonu-
cleotide (AICAR) or metformin, 2 drugs that promote the activa-
tion of AMPK (41, 42), significantly suppressed the effect of LKB1 
knockdown on CCL2 levels, suggesting that LKB1 regulates CCL2 
via AMPK (Figure 2B). Concordantly, AICAR and metformin also 
suppressed CCL2 production in the nontarget controls, further 
emphasizing that AMPK normally suppresses CCL2 production 
even when functional LKB1 is present. The restoration of pAMPK 
(Thr172) levels was only partial in shRNA1 and -2 knockdown 
cells, consistent with the fact that LKB1 is the major (but not sole) 
Thr172 kinase in most cells (43) and also with the observation that 
AICAR and metformin only partially restored CCL2 levels (Figure 
2, B and C). Finally, functional inactivation of AMPK via shRNA-
mediated knockdown of the catalytic subunits AMPKα(1/2) led to 
significantly increased CCL2 secretion (Figure 2, D and E). Thus, 
taken together, these results demonstrate that the LKB1/AMPK 
axis regulates CCL2 production within EM cells.
Misregulation of CCL2 in an Lkb1-based genetically engineered 
murine endometrial cancer model. To further investigate these find-
ings in vivo, we took advantage of a well-described mouse model 
of endometrial cancer based on Lkb1 ablation. In this model, 
homozygous deletion of Lkb1 in endometrial epithelium with the 
Sprr2f-Cre driver results in well-differentiated but highly aggres-
sive cancers with early invasion beginning at 12 weeks of age and 
all females eventually succumbing to the relentlessly progress-
ing cancers (10, 11, 44). As previously described (11), Sprr2f-Cre; 
Figure 4. LKB1 loss in endometrium promotes 
recruitment of macrophages that express 
markers associated with alternative macro-
phage activation. Experiments were conducted 
in 12-week-old animals at proestrus. (A) Macro-
phage density by F4/80 immunohistochemis-
try. (B) Quantitation of macrophages in uterine 
tissue sections immunostained for F4/80. 
Positive cells were counted in 5 separate 
fields and normalized by total area for every 
mouse analyzed (n = 5 for Lkb1+/+, n = 6 for 
Lkb1–/– mice). There were significantly increased 
macrophage numbers in Lkb1–/– endometrium. 
*P < 0.005, per Student’s t test. (C) Presence of 
alternatively activated macrophages character-
ized by ARG1 and CD163 expression. Uterine 
tumor sections were stained with F4/80 and 
CD163 or ARG1. Arrows in the inset highlight 
F4/80 cells that are also positive for the other 
markers. Scale bars: 50 μm. Error bars = SEM.
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led us to investigate the potential contribution of tumor-associated 
macrophages (TAMs) in the growth and progression of Lkb1-driven 
endometrial cancers. We employed the murine macrophage mark-
er F4/80 to quantitate macrophage density in uterine tissue sec-
tions at 12 weeks of age. There was a significant increase (per unit 
area) in the number of endometrial F4/80+ macrophages in Lkb1–/– 
mice relative to controls (Figure 4, A and B). Since the density of 
inflammatory cells varies throughout the murine estrus cycle (48), 
these studies were performed on mice at proestrus (as determined 
by routine exfoliated vaginal cell cytology). In contrast, tumors 
from 3 distinct genetically engineered mouse models of endome-
trial cancer characterized by loss of (a) Pten, (b) Pten and Mig-6 
(49–54), or (c) Pot1a and p53 (55, 56) did not exhibit significantly 
increased F4/80+ cells (Supplemental Figure 2, A and B), support-
ing the notion that elevated macrophage recruitment is a relatively 
specific feature of LKB1-driven endometrial cancers.
TAMs can have anti- or protumor effects depending on the 
tumor type, age and size of tumor, and other variables (57). It is 
believed that alternatively activated macrophages, known as 
M2 macrophages, promote tumor growth and invasion through 
immune suppression and local metabolic effects (58, 59). M2 
macrophages can be distinguished by various markers including 
CD163 and arginase I (ARG1) (60). Most macrophages in Lkb1–/– 
tumors expressed CD163 and ARG1, suggesting that TAMs in Lkb1 
endometrial tumors are generally tumor promoting and express 
markers previously associated with tumor-promoting macro-
phage subtypes (Figure 4C).
To assess the contribution of macrophages to tumor progres-
sion, we treated Lkb1–/– mice with liposome-encapsulated clodro-
nate, which is selectively phagocytized by macrophages, result-
ing in their apoptosis and depletion (61). Free clodronate (i.e., 
released from the dying macrophages) has an extremely short 
Figure 5. TAMs in Lkb1-driven endometrial cancers promote invasion and accelerate tumor progression. Tumor-bearing Lkb1–/– animals were treated with 
liposomal PBS (n = 4) or liposomal clodronate (n = 4) for 9 weeks. (A) Confirmation of systemic macrophage depletion. Among diverse organs, only spleen 
showed decrease in mass following the clodronate regimen, as expected (macrophages make up a significant percentage of cells in the spleen). (B) F4/80 
immunohistochemistry of uterine tissue section confirming macrophage depletion following treatment with clodronate. (C) H&E staining showing greatly 
decreased myometrial invasion in clodronate-treated Lkb1–/– mice. e, endometrium; m, myometrium; dashed lines, endometrial/myometrial interface; 
asterisks, invasive tumor glands. Note that endometrial glands are normally present only in the endometrium; hence, the greatly decreased myometrial 
involvement following clodronate is consistent with slowed tumor progression. (D) Tumor burden, as determined by uterine weight at conclusion of treat-
ment. There was a significant reduction in tumor mass in clodronate-treated animals. *P < 0.01, Student’s t test. (E) Gross photographs of uteri at conclu-
sion of treatment. Weights for uteri in grams shown in lower left-hand corner. Scale bars: 50 μm (B and C). Error bars = SEM.
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half-life and does not have long-term systemic effects (62). Nine-
week-old females were treated with intraperitoneal injections of 
liposomal clodronate or liposomal PBS (control) for 9 weeks and 
then necropsied. The treatment was well tolerated by all animals, 
with no apparent side effects, deaths, or overall weight loss at any 
point in the treatment regimen. Among diverse control organs, 
only the spleen showed a reduction in weight, consistent with sys-
temic macrophage depletion, as red pulp macrophages constitute 
a large cell population in spleen (Figure 5A). F4/80 immunostain-
ing showed significantly fewer macrophages within the endome-
trium, confirming the effectiveness of clodronate in depleting 
uterine macrophages (Figure 5B).
Remarkably, macrophage depletion significantly inhibited 
tumor progression. Whereas invasive tumor glands were abundant 
and diffuse in the myometria of untreated animals at the end of the 
regimen (i.e. at 18 weeks of age), such invasive glands were greatly 
diminished following clodronate treatment (Figure 5C). Concor-
dantly, uterine tumor burden was dramatically decreased follow-
ing clodronate treatment (Figure 5D), with a 10× reduction in over-
all uterine tumor weights (P = 0.001), a difference readily apparent 
by gross examination of the tumorous uteri (Figure 5E). While 
Lkb1–/– tumors exhibited a modest elevation of neutrophils (but not 
CD3+ mature lymphocytes), clodronate treatment did not deplete 
neutrophils or lymphocytes in Lkb1–/– tumors (Supplemental Fig-
ure 3, A and B), consistent with specific depletion of macrophages 
and arguing that slowed tumor progression in clodronate-treated 
animals was due to depletion of macrophages. These experiments 
thus demonstrate that the TAMs recruited to Lkb1-driven endome-
trial cancers have a predominantly tumor-promoting effect.
Dependence of Lkb1-driven endometrial tumor progression on 
CCL2. These experiments were provocative in showing that the 
TAMs recruited in the context of LKB1 loss and ensuing CCL2 
overproduction promote tumor progression. However, these stud-
ies did not formally establish a role of CCL2 in this process. To 
rigorously explore this question, an additional cohort of mice was 
generated by breeding Sprr2f-Cre and the Lkb1 floxed allele into 
a Ccl2-deficient background. Ccl2-null mice, described in prior 
studies, are externally normal and fertile (63). Absence of circulat-
ing CCL2 in Ccl2–/– mice was confirmed by ELISA (Supplemental 
Figure 4A). Sprr2f-Cre; Lkb1f/f; Ccl2–/– mice (hereafter abbreviated 
as Lkb1–/–; Ccl2–/–) were born at expected Mendelian ratios. A cohort 
of Lkb1–/–; Ccl2–/– females, together with sibling Lkb1–/– and Lkb1+/+ 
cohorts, was allowed to age for survival analysis. No tumors were 
observed in Lkb1+/+ controls. However, loss of CCL2 increased 
maximal life span of Lkb1 conditional knockout mice from 301 to 
406 days, with a statistically significant extension of overall sur-
vival (P = 0.004, log-rank test) (Figure 6A). To further study tumor 
progression, a set of animals separate from the survival cohorts 
was euthanized at 26 weeks of age. Uterine tumor burden was sig-
nificantly decreased (>2×) in Lkb1–/–; Ccl2–/– versus Lkb1–/– females 
(P < 0.001; n = 11 Lkb1–/– and n = 8 Lkb1–/–; Ccl2–/–) (Figure 6, B and 
C). Thus, although genetic ablation of CCL2 did not entirely sup-
press the formation and progression of Lkb1-driven endometrial 
cancers, it did significantly slow the progression of these tumors, 
confirming that CCL2 is a critical mediator of LKB1 loss in the 
context of endometrial cancer growth and progression in vivo.
Uterine macrophages were further analyzed and quantitated 
by flow cytometry for F4/80 and CCR2, another general mac-
rophage marker and the receptor for CCL2 (64). These analy-
ses demonstrated that, at 26 weeks, both F4/80+ and F4/80+/
CCR2+ double-positive uterine macrophages were significantly 
decreased in Lkb1–/–; Ccl2–/– versus Lkb1–/– females (Figure 7A), 
which was further confirmed in F4/80-immunostained uterine 
sections (Figure 7B). These analyses confirmed the existence of 
a uterine macrophage population capable of responding to CCL2 
and, together with our prior observations, are consistent with the 
idea that CCR2+ macrophages play a role in tumor progression 
in the Lkb1 model. Interestingly, while Lkb1-null mice harbored 
increased circulating monocytes and decreased lymphocytes, 
these effects were reversed by loss of CCL2 (n = 6 Lkb1–/–, n = 3 
Lkb1–/–; Ccl2–/–) (Figure 7C). Overall, these results suggest that 
CCL2 plays an important part in Lkb1-driven tumorigenesis by 
Figure 6. Endometrial cancers driven by LKB1 loss are CCL2 
dependent in vivo. (A) Survival curves for 2 experimental geno-
types and control Lkb1+/+; statistical significance was calculated 
by log-rank test. (B) Tumor burden at 180 days (n = 11 Lkb1–/–,  
n = 8 Lkb1–/–; Ccl2–/–) as determined by uterine weight, *P < 0.001, 
Student’s t test (C) Gross photographs of uteri at 180 days of 
age. Weights for uteri in grams shown in lower left-hand corner. 
Left uterus image was cropped, rotated 180° to align uterine 
horns with those of the right uterus image, and the image 
placed on a black background. Error bars = SEM.
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ly validated for detection of endogenous LKB1 protein in PEFFT 
(65). Sufficient tumor was present to permit scoring of all 3 mark-
ers for n = 175 cases of endometrial cancer. Based on the observed 
patterns and intensity of staining, a semiquantitative 0–3 scoring 
scale was established for all 3 markers (illustrated in Supplemen-
tal Figure 6; see also Methods for detailed description of scoring 
criteria). Note that, while CCL2 and LKB1 IHC were used to assess 
protein levels in a semiquantitative manner, CD68 immunostains 
were used to assess macrophage density. In some primary tumors, 
CCL2 was expressed primarily on the apical epithelial cytoplasm, 
while in other tumors, CCL2 was located diffusely throughout the 
apical and basal cytoplasm (Supplemental Figure 6B).
After scoring was completed, heat maps were generated to 
explore associations among the markers. There was a strong nega-
tive association between CCL2 and LKB1, both for grade 1 and grade 
1–3 endometrial cancers (P = 0.00019; τκ = –0.45 and P = 0.000278; 
τκ = –0.19 respectively). There was also a strong negative association 
between CD68 (i.e., macrophage density) and LKB1 scores, again 
in both grade 1 and grade 1–3 cancers (P = 0.000373; τκ = –0.43 and 
P = 2.72 × 10–8; τκ = –0.36, respectively) (Figure 8A).
We then categorized expression of each protein by clinical 
stage in addition to grade. FIGO (International Federation of 
Gynecology and Obstetrics, 1988) stage 1A tumors are defined by 
the absence of myometrial invasion, whereas 1B tumors invade 
stimulating (a) increased peripheral monocyte numbers and (b) 
monocyte recruitment to the endometrial tumors.
Evidence that the LKB1/CCL2/TAM axis contributes to the pro-
gression of human endometrial cancer. To study the LKB1/CCL2/
TAM axis in human tumors, an endometrial cancer tissue micro-
array (TMA) was constructed with duplicate cores for nearly 200 
independent primary tumors, predominantly of the endometrioid 
subtype, which is the most common (Supplemental Table 3). TMA 
slides were stained for CCL2, CD68 (human macrophage marker), 
and LKB1. Since many antibodies do not reliably detect their cog-
nate antigen in paraffin-embedded formalin-fixed tissues (PEFFT) 
and few immunohistochemical (IHC) studies have been conducted 
on CCL2 in human PEFFT, we first validated our CCL2 IHC pro-
tocol on the Ishikawa endometrial cancer cell line overexpressing 
CCL2. After fixation in 10% buffered formalin followed by paraffin 
embedding (to simulate processing of human tissues in the clinical 
pathology laboratory), the CCL2-overexpressing cells gave a much 
higher signal than control Ishikawa cells (Supplemental Figure 5). 
Immunohistochemistry of serial step sections (in a subset of 10 
tumors) with the macrophage-specific scavenging receptor CD163 
gave virtually superimposable patterns of expression and staining 
scores as CD68, further validating the use of CD68 as a macro-
phage marker in endometrial tumors (our unpublished observa-
tions). For detection of LKB1, we employed an IHC assay previous-
Figure 7. LKB1 tumor-associated phenotypes including recruitment of macrophages and systemic effects are CCL2 dependent. (A) Left: representa-
tive dot plot displaying 1 of 3 independent experiments used to quantitate F4/80+/CCR2+ macrophages in tumors driven by Sprr2f-Cre at 180 days. Right: 
Lkb1–/– tumorous uteri, which overexpress CCL2, contained a significantly greater percentage of F4/80+/CCR2+ and total F4/80+ cells than Lkb1–/–; Ccl2–/– 
tumors on average from 3 independent experiments. These data demonstrate that LKB1 loss leads to increased macrophage recruitment to the TME in a 
CCL2-dependent manner. (B) Macrophage density by F4/80 staining confirmed the presence of fewer macrophages in Lkb1–/–; Ccl2–/– endometrial tumors. 
(C) Complete blood counts showing CCL2-dependent effects in circulating monocyte and lymphocyte numbers. *P < 0.05; **P < 0.001; ***P < 0.0005, 
Student’s t test. Scale bars: 50 μm. Error bars = SEM.
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the primary tumor, leading to increased macrophage recruitment 
to the tumor. Prior studies also consistently demonstrated a strong 
association between TAM density in primary endometrial tumors 
and grade, stage, and clinical outcome (67–70).
Discussion
At the initiation of these studies, the paradoxically aggressive 
phenotypes we had previously described for LKB1-deficient uter-
ine cancers (8, 11) strongly suggested that LKB1 acted as a uter-
ine tumor suppressor via unknown biological mechanisms. This 
study, which began with expression profiling of isogenic cell lines 
to pinpoint such biological pathways, demonstrated that LKB1 
regulates the transcription of multiple secreted factors of poten-
tial relevance to LKB1’s actions as a tumor suppressor. Additional 
through less than half of the myometrium and 1C tumors invade 
through greater than half of the myometrial thickness (66). There 
was a trend toward higher numbers of cases with low LKB1 (pro-
tein score = 0) expression among stage 1C cases, although this 
did not achieve statistical significance. However, there was a sta-
tistically significant (P < 0.001) increase in cases with low LKB1 
expression in grade 3 versus grade 1. For CCL2 and CD68, there 
was again a trend toward increased expression in stage 1C versus 
1A that did not achieve significance, while there was a statistically 
significant increase in cases expressing high levels of these can-
cers in grade 1 versus grade 3 tumors (P < 0.005, Figure 8B). These 
studies, conducted in a large set of human primary endometrial 
cancers, provide strong support for a model where LKB1 loss pro-
motes tumor progression through increased CCL2 secretion by 
Figure 8. Low LKB1 protein levels in primary human endometrial cancers are strongly correlated with high CCL2 expression and increased macrophage 
density. A human endometrial cancer TMA was stained and scored for each marker per the schematic in Supplemental Figure 6. A total of 175 separate 
cases of primary endometrial cancer were scored. Pair-wise correlations were evaluated by Kendall’s τ coefficient, with P values determined by 2-tailed 
t tests. (A) Heat maps showing significant negative correlations among grade 1 and grade 1–3 endometrial adenocarcinomas. (B) Top panels: number of 
cases with specific staining scores (grades 0–3) among tumors of different clinical stages (FIGO 1A, 1B, 1C). Of cases with more than 50% myometrial 
invasion (defined as stage 1C), the percentage with low LKB1 expression or high CCL2/CD68 expression was significantly increased. Bottom panels: number 
of cases with specific staining scores (grades 0–3) among tumors of different histopathological grades (grades 1, 2, 3). There was a significantly greater 
percentage of cases expressing low levels of LKB1 protein among high-grade tumors (n = 113). Additionally, there was a significantly greater percentage of 
cases expressing high levels of CCL2 (n = 113) and CD68 (n = 113) among high-grade tumors. *P < 0.005; **P < 0.001, Fisher’s exact t test.
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CCL2 produced by malignant epithelial cells within a tumor 
serves to recruit monocytes and promote their differentiation 
(paracrine effects), but can also directly affect the malignant cells 
themselves (autocrine effects). High-grade urothelial (bladder) car-
cinomas expressing high levels of CCL2 stimulate their own growth, 
migration, and invasive capacity in a cell-autonomous, CCR2-
dependent manner (38). CCL2 also promotes prostate cancer che-
motaxis, invasion, and metastasis via CCR2 and its downstream 
effectors, which include PI3K/AKT, Rac, and RhoA (71). Although 
we did not directly evaluate the contributions of such CCL2-depen-
dent autocrine mechanisms on endometrial cancer progression in 
our models, we have documented expression of the CCR2 receptor 
protein in all uterine cancer cell lines we have analyzed, including 
both endometrial and cervical cancer cell lines (our unpublished 
observations). Thus, we believe that such autocrine effects are not 
only plausible but likely and deserve further investigation. Another 
intriguing possibility is that CCL2/CCR2 interactions could have 
cell-autonomous effects on intracellular metabolism, which might 
in turn further synergize with the LKB1/AMPK/mTOR axis. The 
specific mechanisms and signaling cascades by which the LKB1/
AMPK axis regulates CCL2 expression also remain an important 
area of inquiry deserving further investigations.
Increased TAM density in human endometrial cancer is asso-
ciated with a worse clinical prognosis. Macrophages are the most 
abundant leukocyte population in mouse and human endometri-
um, where they serve diverse physiologic functions during endo-
metrial cycling and pregnancy. In a large recent study of n = 163 
primary endometrial cancers, increased TAM density correlated 
strongly with advanced tumor stage and grade, lymphovascular 
space involvement, and decreased recurrence-free and overall 
survival. Interestingly, intratumoral density of other immune cel-
lular subsets, such as Tregs, did not correlate with these clinical 
parameters (70). Both our mouse and human studies confirm that 
TAMs in primary endometrial tumors have protumorigenic roles 
and implicate the LKB1/AMPK axis as an important regulator of 
TAM density in tumors via CCL2.
CCL2 exerts its biological roles principally via CCR2, which 
is highly expressed in classical monocytes. Conversely, CCR2 is 
not known to be activated by any chemokines other than CCL2. 
This mutual relationship suggests that, for tumors characterized 
by high levels of CCL2, inhibition of CCR2 through neutralizing 
antibodies or through small molecule drugs in clinical develop-
ment might prove a useful therapeutic approach (76). New ther-
apeutic strategies for endometrial cancer are urgently needed, 
as there are as yet no curative treatments for advanced disease, 
although recently, objective responses have been documented for 
temsirolimus, an mTOR inhibitor (77). Our study and prior data 
demonstrating that TAM density is an important driver of human 
endometrial tumor progression lend further support to the notion 
that the LKB1/CCL2/TAM axis is an attractive target for new ther-
apeutic strategies. Our demonstration that genetic inactivation of 
Ccl2 suppresses Lkb1-driven tumors in vivo also lends strong sup-
port for this idea. Further validation for anti-CCL2/CCR2 thera-
peutic strategies and additional biological insights are likely to be 
gained by additional investigations of the Lkb1–/– mouse model, 
particularly since the complete penetrance of endometrial adeno-
carcinomas and stereotypical tumor progression make this a high-
investigations, which included analyses of a genetically engi-
neered mouse model as well as primary human tumors, led to the 
unexpected discovery that one of these factors — the chemokine 
CCL2 — is a physiologically important effector of Lkb1-driven 
endometrial cancers. Our studies revealed an unanticipated but 
essential role for LKB1 in the control of the TME in addition to 
the well-known effects of LKB1 on cell-autonomous metabo-
lism and signaling. Specifically, we showed that LKB1 loss in EM 
cells leads to increased expression and secretion of CCL2 in a 
cell-autonomous manner and that increased intratumoral CCL2 
derived from epithelial cells in turn leads to accelerated tumor 
growth via the recruitment of protumorigenic macrophages. Our 
study thus forges new links among endometrial carcinogenesis, 
the LKB1 tumor suppressor, CCL2/CCR2, and TAMs and pro-
vides insights into the particularly aggressive tumor phenotypes 
associated with LKB1 loss.
Our data are in line with growing evidence implicating inflam-
matory chemokines in general, and CCL2 in particular, with tumor 
progression. Chronic inflammation is a hallmark of cancer and 
linked with the initiation and progression of carcinomas. In carci-
nomas of the breast, prostate, colon, liver, and bladder, production 
of CCL2 by tumor cells is associated with increased infiltration of 
TAMs and early clinical relapse (38, 71). For example, in uterine 
cervical cancer, absence of CCL2 mRNA expression correlated 
with decreased TAM density and improved overall survival (72). 
Our study is thus consistent with prior data showing that CCL2 
expression is a significant prognostic factor in cancer (38).
A variety of cell-surface receptors expressed on monocytes/
macrophages together with their corresponding ligands, including 
CCR2/CCL2, VEGFR1/VEGF-A, and CX3CR1/CX3CL1, regulate 
monocyte recruitment into tumors. In general, the expression of 
one or more of these ligands positively correlates with TAM num-
bers. CCL2 is a potent chemoattractant of monocytes/macrophages 
and appears to be the main determinant of monocyte/macrophage 
recruitment within primary tumors. CCL2 production in distant 
metastatic deposits can also lead to the recruitment of monocytes 
and thereby promote growth of these deposits (73). Normal, unin-
jured tissues produce low levels of CCL2, whereas tumors often 
express and produce higher CCL2 levels. Some monocyte chemo-
attractants (e.g., VEGF-A) are produced within carcinomas by non-
epithelial cells (such as fibroblasts). In contrast, CCL2 is largely 
produced by the malignant epithelial cells, although other cells in 
the primary TME can also serve as sources of CCL2.
In our model, CCL2 produced by the primary endometrial 
cancer was detectable in the circulation. Furthermore, increased 
circulating monocytes were observed in these Lkb1–/– female mice, 
consistent with the well-established role of the CCL2/CCR2 
axis in the mobilization of monocytes from the bone marrow to 
the blood (74) and further signifying that the CCL2 produced by 
tumors can exert systemic as well as local effects. Consistent with 
this idea, serum CCL2 (sCCL2) represents a potential circulating 
biomarker to monitor tumor progression or predict progression 
risk. In patients with gastric and hepatocellular carcinomas, pre-
operative levels of sCCL2 were significantly higher than in control 
patients and correlated with stage (75). However, studies of sCCL2 
in cancer are in their early stages, and data on sCCL2 circulating 
levels in women with endometrial cancer are not yet available.
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RNA from nontarget, shRNA1, and shRNA2 cells were loaded onto the 
chip. All original microarray data were deposited in the NCBI’s Gene 
Expression Omnibus (GEO GSE67629).
Array analysis was performed using Illumina GenomeStudio 
2011 software v2011.1. A 95% confidence interval was used to fil-
ter out nonspecific binding of probes to RNA. Probe intensities of 
shRNA1 or shRNA2 were normalized to nontarget probe intensities, 
and resultant values of less than 3× were excluded. Intensity values 
that differed in directionality between shRNA1 and shRNA2 were 
additionally filtered out, leaving 59 probe sets unique to shRNA1, 142 
probe sets unique to shRNA2, and 43 probe sets in common. Gene 
ontology analysis was performed on tabulated genes from the filtered 
probe sets using WebGestalt (78).
Lysate preparation for immunoblotting and ELISA. Cells in culture 
were washed in PBS following media aspiration. Cells were mechani-
cally detached from culture dishes in RIPA buffer (Pierce, catalog 
89900) supplemented with protease (Roche, catalog 11836170001) 
and phosphatase inhibitors (Sigma-Aldrich, catalog P5726) on ice. 
Normal and cancerous uteri were rinsed in PBS before homogeniza-
tion in RIPA buffer. Protein from cells and tissue lysate was quanti-
fied using the Pierce BCA Protein Assay Kit (catalog 23227). Equal 
amounts of protein were used for Western blots and ELISA. ELISA 
for murine tumor lysate and sCCL2 was performed using the Mouse/
Rat CCL2/JE/MCP-1 Quantikine ELISA Kit per the manufacturer’s 
instructions (R&D Systems, catalog MJE00).
In vitro cell culture studies. EM cells (nontarget, shRNA1, shRNA2) 
were plated at 75,000 cells/plate in 6-well plates (Corning, catalog 
CLS3516). Cells were allowed to grow for 24 hours, rinsed in PBS, and 
replaced with fresh medium containing either PBS (vehicle), 0.5 mM 
AICAR (Sigma-Aldrich, catalog A9978), or 5 mM metformin (Sigma-
Aldrich, catalog PHR1084). Lysates and conditioned media were har-
vested from cells 24 hours after drug treatment. Western blotting on 
lysates (including nondrug studies) was done using 1:1000 dilutions 
of the following antibodies (Cell Signaling Technologies) in Tris-
buffered saline containing 5% milk: LKB1 (catalog D60C5), pAMPK 
(Thr172) (catalog 2535), AMPK (catalog 2603), pS6 (catalog 4857), 
S6 (catalog 2217), p4EBP1 (catalog 9455), 4EBP1 (catalog 9452), and 
GAPDH (catalog 2118). ELISA on conditioned media (including non-
drug studies) for CCL2 was performed using the Human CCL2/MCP-1 
Quantikine ELISA Kit according to the manufacturer’s instructions 
(R&D Systems, catalog DCP00).
Growth and migration assays were as described (3). CCL2 cDNA 
subcloned into a pDream2.1 plasmid was obtained (Genescript, cata-
log SD0222). Transfection into Ishikawa cells (Sigma-Aldrich, cata-
log 99040201-1VL) was performed with Lipofectamine reagent (Life 
Technologies, catalog 11668) per the manufacturer’s instructions. Aga-
rose plugs for testing of IHC protocols were prepared as described (65).
Mouse husbandry and procedures involving tissues or live animals. 
Mice were housed in a pathogen-free animal facility in microisolator 
cages and fed ad libitum on standard chow. Control animals (Lkb1f/f) 
and Lkb1–/– endometrial Lkb1-knockout mice (FVB/n genetic back-
ground, backcrossed > 10 generations) were bred and generated as 
previously described (11). Ccl2–/– mice (B6.129S4-Ccl2tm1Rol/J) were 
obtained from Jackson Laboratories. Tissue sections from Pten and 
Pten/Mig-6 uteri were a gift from Jae-Wook Jeong (Michigan State 
University, East Lansing, Michigan, USA) (49–54). Mouse blood was 
obtained by retroorbital bleeding and collected in EDTA tubes for 
ly tractable model. Taken together, our data indicate that Lkb1–/– 
mice should serve as an optimal preclinical platform for testing 
diverse agents currently in various stages of clinical development, 
including CCL2- or CCR2-neutralizing antibodies or small mol-
ecule inhibitors that target CCR2. It will also be interesting to test 
the efficacy of such agents either alone or in combination with 
agents (such as temsirolimus) likely to synergize with LKB1 loss 
and the ensuing hyperactivation of AMPK/mTOR pathways (11).
Methods
Creation of stable, LKB1 knockdown cell lines by lentiviral shRNA. Non-




indicate complementary 21-bp stem sequences corresponding to 
LKB1 genomic sequences) were cloned into AgeI-EcoRI sites of the 
pLKO.1 vector (Sigma-Aldrich, catalog SHC002). FuGENE HD trans-
fection reagent (Promega, catalog E2311) was used to cotransfect 
each shRNA vector or a nontarget control vector (Sigma-Aldrich, cat-
alog SCH001) with lentiviral packaging plasmid (psPAX2, Addgene 
catalog 12260) and VSV-G envelope–expressing plasmid (pMD2.G, 
Addgene catalog 12259) into HEC293T cells for 15 hours. Transfec-
tion medium was replaced and incubated in fresh media at 37°C for 
24 hours to produce lentivirus particles.
An immortalized, endometrial epithelial cell line (EM cells) 
obtained from Masaki Inoue (Kanazawa School of Medicine, Tokyo, 
Japan) (34) was grown in DMEM/F-12, HEPES buffer (Life Technolo-
gies, catalog 11330) supplemented with 10% FBS. 150,000 EM cells 
were individually infected with lentivirus (nontarget, shRNA1, or 
shRNA2) for 24 hours with polybrene (4 μg/ml) (Sigma-Aldrich, cata-
log H9268), followed by replacement with fresh medium. Stably trans-
fected cells were selected with 1 μg/ml puromycin (Clontech, catalog 
631305) over 1.5 weeks. Three biological replicates of EM cells per len-
tivirus were created to produce a total of 9 cell lines.
For AMPK knockdown experiments, this process was repeated 
using either control shRNA lentiviral particles (Santa Cruz Biotechnol-
ogy Inc., catalog sc1080-80) or AMPKα1/2 shRNA lentiviral particles 
(Santa Cruz Biotechnology Inc., catalog sc-45312-V).
RNA preparation and qRT-PCR. Total mRNA was isolated from EM 
cells using the RNeasy Mini Kit (QIAGEN, catalog 74104). cDNA (0.5 
μg) was synthesized using mRNA via Superscript VILO (Life Technolo-
gies, catalog 11754) and diluted in TaqMan Universal PCR Master Mix 
(Life Technologies, catalog 4304437) with TaqMan probes (Life Tech-
nologies, catalog 4453320) including MXRA5 (Hs01019147_m1), LKB1 
(Hs00176092_m1), CRIP2 (Hs00373842_g1), GCNT2 (Hs00377334_
m1), FABP4 (Hs01086177_m1), CXCL6 (Hs00605742_g1), FST 
(Hs00246256_m1), and CCL2 (Hs00234140_m1). qRT-PCR was per-
formed on master mixes in triplicate using Applied Biosystems Step-
OnePlus Real-Time PCR machine. Ct values per gene were averaged 
before computing fold change by the ΔΔCt method using GAPDH as 
a reference gene and EM nontarget shRNA cells as reference samples.
Microarray and gene ontology analysis. Microarray hybridization 
was performed per the manufacturer’s specifications with 500 ng of 
labeled total RNA. Preparation of samples and loading of RNA onto 
the HumanHT-12 v4 Expression BeadChip was performed by the 
UTSW DNA Microarray Core Facility. Three biological replicates of 
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cytometry was performed using a FACSCalibur and the results were 
analyzed with FlowJo software.
Histological scoring scheme for TMA. The generation of TMA was 
previously described (10). A 4-category classification scheme was 
employed to score protein expression for LKB1 and CCL2 based on 
the staining intensity within epithelium. For CD68, scoring reflected 
macrophage numbers in stroma and epithelium. The 4 categories for 
CD68 were as follows: 0 ≤ 100 macrophages; 1 = 101–200; 2 = 201–
300; and 3 > 300 total macrophages per intact core.
Statistics. Data are presented as mean ± SEM unless otherwise 
indicated. To determine P values, 2-tailed Student’s t tests were per-
formed (unless otherwise indicated). P < 0.05 was considered statisti-
cally significant. For survival curves, Kaplan-Meier analysis was used, 
with statistical comparison among curves performed with the log-rank 
test. Overlap among the 2 shRNA gene sets was calculated by the 
hypergeometric test. Kendall’s τ correlation coefficients were calcu-
lated using Wessa statistics software. Routine statistical analyses were 
performed with either GraphPad Prism (version 6.05) or Microsoft 
Excel. No statistical method was used to predetermine sample size. 
The experiments were not randomized, and the investigators were not 
blinded to allocation during experiments and outcome assessment.
Study approval. Animal studies were approved by the University 
of Texas Southwestern IACUC. Use of human samples was exempt 
from IRB approval due to the use only of anonymized, archival speci-
mens. Experiments were conducted with the approval of and under 
the guidelines of the University of Texas Southwestern Environmental 
Health and Safety Office.
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CBCs (IDEXX ProCyte Dx Hematology Analyzer) or in Eppendorf 
tubes and allowed to coagulate before serum collection. ELISA for 
murine tumor lysate and sCCL2 was performed using the Mouse/
Rat CCL2/JE/MCP-1 Quantikine ELISA Kit per the manufacturer’s 
instructions (R&D Systems, catalog MJE00).
Nine-week-old Lkb1–/– females were treated with intraperitoneal 
injections of liposomal clodronate or liposomal PBS (0.4 ml of suspension 
per 25 g animal weight 4 times a week) for 9 weeks. Liposomal clodronate 
and control liposomes were purchased from Clodronate Liposomes.
Tissue processing, IHC, immunofluorescence. Fixation, sectioning, 
antigen retrieval, blocking, and secondary detection for the following 
antibody dilutions in 2% BSA were performed as previously described 
(65): LKB1 (1:10,000 human tissue, 1:5000 mouse tissue, Cell Sig-
naling Technologies, catalog D60C5F10), CD68 (1:250, Dako, cata-
log M0876), CCL2 (1:250, Sigma-Aldrich, catalog HPA019163), MYP 
(1:250, Abcam, catalog ab9535), CD3 (1:50, Abcam, catalog ab5690) 
and pAMPK (Thr172) (1:75, Cell Signaling Technologies, catalog 
2535). Antigen retrieval for F4/80 immunostaining (1:100, Abd 
Serotec, catalog MCA497) on PEFFT was performed using 0.005% 
pepsin in 0.01 M HCl at 37°C for 15 minutes, followed by water and 
PBS rinses. Blocking and secondary detection for F4/80 were per-
formed as described (65).
Immunofluorescence was performed by embedding frozen tis-
sues in OCT and cryosectioning, followed by 5-minute fixation in 
cold acetone, and blocking in 3% BSA prior to the following antibody 
dilutions in 3% BSA: rat anti-mouse F4/80 (1:100, Abd Serotec), goat 
anti-mouse CD163 (1:50, Santa Cruz Biotechnology Inc., catalog 
sc33560), rabbit anti-mouse Arg1 (1:100, Santa Cruz Biotechnology 
Inc., catalog sc18351), and rat anti-mouse CCL2 (1:50, Clone ECE2, 
Novus Biologicals, catalog NBP1-42312). Secondary antibodies (Life 
Technologies) included the following: Alexa Fluor 488 donkey anti-rat 
(catalog A21208), Alexa Fluor 488 donkey anti-goat (catalog A11055), 
and Alexa Fluor 555 goat anti-rabbit (catalog A21429).
Flow cytometry. Cell suspensions were obtained from mice by 
enzymatic digestion and washed in FACS buffer (1% BSA, 0.01% 
NaN3 in PBS). Cells were blocked for 5 minutes with Fc blocking 
reagent (BD Biosciences — Pharmingen, catalog 553142) prior to 
labeling with fluorescent-conjugated antibodies diluted in FACS buf-
fer: F4/80-PerCy5.5 (1:200, Tonbo Biosciences, catalog 65-4801) 
and CCR2-APC (1:50, R&D Systems, catalog FAB5538A). Flow 
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